What is claimed is:

1. A stable aqueous pharmaceutical formulation comprising

(a) a bispecific antibody construct,

(b) a saccharide,

(c) a surfactant, and

(d) a buffer,

wherein the pH of the formulation is from 4.8 to 5.5.

2. The formulation of claim 1, wherein the pH of the formulation is from 4.8 to 5.3.

3. The formulation of claim 1 or 2, wherein the pH of the formulation is about 5.2.

4. The formulation of any one of claims 1-3, wherein the saccharide is a monosaccharide or a disaccharide.

5. The formulation of any one of claims 1-4, wherein the saccharide is glucose, galactose, fructose, xylose, sucrose, lactose, maltose, trehalose, sorbitol, mannitol, or xylitol.

6. The formulation of any one of claims 1-5, wherein the surfactant is a nonionic surfactant.

7. The formulation of any one of claims 1-6, wherein the surfactant is polysorbate 20, polysorbate 40, polysorbate 60, polysorbate 80, poloxamer 188, poloxamer 407, or triton x-100.

8. The formulation of claim 7, wherein the surfactant is polysorbate 20, polysorbate 40, polysorbate 60, or polysorbate 80.

9. The formulation of claim 7, wherein the surfactant is poloxamer 188 or poloxamer 407.

10. The formulation of any one of claims 1-9, wherein the buffer is an acetate buffer, a glutamate buffer, a citrate buffer, a lactic buffer, a succinate buffer, a tartrate buffer, a fumarate buffer, a maleate buffer, a histidine buffer, or a phosphate buffer.

11. The formulation of any one of claims 1-10, wherein the formulation comprises the bispecific antibody construct at a concentration of from 0.1 mg/ml to 20 mg/ml.

12. The formulation of any one of claims 1-12, wherein the bispecific antibody construct comprises a first binding domain that binds to a target cell surface antigen and a second binding domain that binds to human CD3 on the surface of a T cell.

13. The formulation of claim 12, further comprising a third domain comprising, in an amino to carboxyl order, hinge-CH2 domain-CH3 domain-linker-hinge-CH2 domain-CH3 domain.

14. The formulation of claim 13, wherein each of the first and second binding domains comprise a VH region and a VL region.

15. The formulation of claim 13 or claim 14, wherein the bispecific antibody construct is a single chain antibody construct.

16. The formulation of any one of claims 12-15, wherein the target cell surface antigen is CDH19, MSLN, DLL3, FLT3, EGFR, EGFRvlll, BCMA, PSMA, CD33, CD19, CD70, MUC17 or CLDN18.2.

17. The formulation of any one of claims 12-16, wherein the first binding domain of the bispecific antibody construct comprises a set of 6 CDRs set forth in (a) SEQ ID NOs: 24-29, (b) SEQ ID NOs: 34-39, (c) SEQ ID NOs: 78-83, (d) SEQ ID NOs: 10-15, (e) SEQ ID NOs: 46-51, (f) SEQ ID NOs: 88-93, (g) SEQ ID NOs: 67-72, (h) SEQ ID NOs: 56-61, (i) SEQ ID NOs: 112-117, (j) SEQ ID NOs: 100-105, (k) SEQ ID NOs:148-153, SEQ ID NOs: 157-162, or SEQ ID NOs: 166-171, or SEQ ID NOs: 175-180, (l) SEQ ID NOs:132-137, or (m) 123-128.

18. The formulation of any one of claims 12-17, wherein the second binding domain of the bispecific antibody construct comprises a set of 6 CDRs set forth in SEQ ID NOs: 1-6.

19. The formulation of any one of claims 12-18, wherein the first binding domain comprises:

(a) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 30 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 31;

(b) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 40 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 41;

(c) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 84 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 85;

(d) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 16 or 17 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 18 or 19;

(e) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 52 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 53;

(f) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 94 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 95;

(g) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 73 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 74;

(h) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 62 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 63;

(i) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 118 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 119;

(j) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 154, 163,172, or 181 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 155, 164, 173, or 182;

(k) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 106 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 107;

(l) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 138 or 143 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 139 or 144; or

(m) a VH region comprising an amino acid sequence set forth in SEQ ID NO: 129 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 130.

20. The formulation of any one of claims 12-19, wherein the second binding domain comprises a VH region comprising an amino acid sequence set forth in SEQ ID NO: 7 and a VL region comprising an amino acid sequence set forth in SEQ ID NO: 8.

21. The formulation of any one of claims 12-20, wherein the bispecific antibody construct comprises amino acid sequence set forth in SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 33, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 55, SEQ ID NO: 65, SEQ ID NO: 66, SEQ ID NO: 55, SEQ ID NO: 76, SEQ ID NO: 77, SEQ ID NO: 87, SEQ ID NO: 97, SEQ ID NO: 98, SEQ ID NO: 99,

SEQ ID NO: 109, SEQ ID NO: 110, SEQ ID NO: 111, SEQ ID NO: 121, SEQ ID NO: 122, SEQ ID NO: 131, SEQ ID NO: 141, SEQ ID NO: 142, SEQ ID NO: 146, SEQ ID NO: 147, SEQ ID NO: 156, SEQ ID NO: 165, SEQ ID NO: 174, SEQ ID NO: 183, SEQ ID NO: 184, SEQ ID NO: 185, SEQ ID NO: 186, SEQ ID NO: 187, or SEQ ID NO: 188.

22. The formulation of any one of claims 1-21, wherein the formulation comprises less than about 10% of low molecule weight (LMW) clipping product of the bispecific antibody construct after storage at about 40˚C for one month.

23. The formulation of claim 22, wherein the formulation comprises less than about 8% of low molecule weight (LMW) clipping product of the bispecific antibody construct after storage at about 40˚C for one month.

24. The formulation of claim 22 or 23, wherein the formulation comprises less than about 5% of low molecule weight (LMW) clipping product of the bispecific antibody construct after storage at about 40˚C for one month.

25. The formulation of any one of claims 22-24, wherein the formulation comprises less than about 3% of low molecule weight (LMW) clipping product of the bispecific antibody construct after storage at about 40˚C for one month.

26. The formulation of any one of claims 22-25, wherein the formulation comprises less than about 5% of high molecule weight (HMW) aggregates of the bispecific antibody construct after one month's storage at about 40˚C.

27. The formulation of any one of claims 22-26, wherein the relative potency of the bispecific antibody construct is greater than 30% after one month at about 40˚C.

28. The formulation of any one of claims 22-26, wherein the relative potency of the bispecific antibody construct is greater than 50% after one month at about 40˚C.

29. The formulation of any one of claims 22-26, wherein the relative potency of the bispecific antibody construct is greater than 60% after one month at about 40˚C.

30. Use of the formulation of any one of claims 1-29 in the manufacture of a medicament for treating cancer in a subject in need thereof.

31. The use of claim 30, wherein the use further comprises diluting the formulation with a pharmaceutically acceptable liquid before administration to the subject.

32. The use of claim 30 or 31, wherein the formulation is to be administered by intravenous administration.

33. A formulation of any one of claims 1-29 for use in therapy.